Slide 1: ClearPoint Neuro
CLEARPOINT NEURO WE POINT THE WAY. AY . Nasdaq: CLPT May 2022
Slide 2: Forward-looking statements
Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plan
Slide 3: Our Company: Two Opportunities, One Platform
Our Company ClearPoint Neuro: Two Opportunities, One Platform CLEARPOINT NEUR *« ACommon Installed Base Platform and Clinical Specialist Support team 35 Active Indications totaling more than 1 million patients diagnosed annually * A$12B+ Potential Total Addressable Market A Biologics & Drug Delivery
Slide 4: ClearPoint Neuro: A Proven Platform
Our Company ClearPoint Neuro: A Proven Platform Key Products: FDA C€ Marked Platforms HEADQUARTERS MANUFACTURING EUROPEAN HEADQUARTERS Solana Beach, CA Irvine, CA London, UK 2022 EXPECTED REVENUE CASH $21-22m $49.7m" - U.S. PATENTS ISSUED GROSS MARGIN Razor / Razorblade u 75 4) 69% (A,C) model with
Slide 5: Limitations of Traditional Stereotactic Neurosurgery
Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible CLEARPOI
Slide 6: Our Platform — Procedure Overview
Our Platform — Procedure Overview The ClearPoint® Neuro Navigation System 388; CLEARPOINT © 2022 CLEARPOINT NEURO 6 38° NEURO
Slide 7: SmartFrame XG and SmartFrame Array
SmartFrame® XG SmartFrame Array™ A eo (7 AY pep SmartFrame Array Tower with “virtual array” Software and next generation robotic system with increased automation and enabling software* ClearPoint plans to translate more than 10 years of experience and over 5,000 cases performed in the complex MRI su
Slide 8: The ClearPoint Maestro Brain Model
Our Platform The ClearPoint ‘Maestro’ Brain Model” Licensed and Jointly Developed with Philips 1. Shape Constrained, triangular mesh model enables point- based correspondence across multiple subjects 2. Fast and capable of peri-procedural imaging without CPU acceleration 3. This model is the basis f
Slide 9: Installed base of centers
UC San Francisco - : “University of Wisconsin 2 _ e enmark) ‘Stanford University He a University of Michigan S ~~ Mazowiecki Szpital Brodnowski Warsaw, Polatid * Stanford Children’s Hospital University of Mirinesota : UCSF Benioff Children’s. —ClevelandClinic. | . . CHOA Scottish Rite * San Francisc
Slide 10: Our MRI-guided therapy platform partners
SIEMENS @ IMRIS es CLEARPOINT Our MRI-guided therapy platform is currently being used to... PTC) Medtronic Sle ) Abbott ay BlueRock ey) Thetapsultes Boston, a Scientific SSENE uniQure NEURO charles river ..Approximately 45 total commercial and academic partners Medtronic MONTERIS MEDICAL ee cece se
Slide 11: Growth in Case Volume and Revenue
2013 - 2022 Growth in Case Volume and Revenue 2013 2014 2015 CLEARPOINT covib impact on Elective 801 Procedures 682* 2016 2017 2018 2019 2020 aus 2021 Biologics and Drug Delivery ™ Capital and Software Functional Neurosurgery $3.4 ! $5.2 [$5.4 2014 «2015. «= 2016«= 2017'S - 2018 $16.3 6.3 $8.4 2020
Slide 12: ClearPoint Neuro Market Opportunity — United States
Global E: ClearPoint Neuro Market Opportunity — United States aad ~2 X U.S. Revenue ~$12B+ Opportunity: Empowering Multiple Treatment Options for 35+ Indications* feast 7 7 a Pillar 1: Incremental Revenue Parkinson’s Disease 1,000,000 60,000" O O $270 M-$1.35B Drug Resistant Epilepsy 1,000,000? 11,0
Slide 13: Market Opportunity Citations & Footnotes
ClearPoint Neuro Market Opportunity — United States Citations & Footnotes “Parkinson's Disease Statistics,” Parkinson's News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older Neurona Therapeutics. (2021 Novembe
Slide 14: Innovation Pipeline
Innovation Pipeline ClearPoint Neuro is Dedicated to Innovation in the Neuro Space Expected 2022 First-Pre-Clinical/Clinical Use* ClearPoint Maestro™ Brain Model Revolution™ Robotic-Assisted Expanded Pre-Clinical Development Services for Pharma Pre-Clinical Head Fixation Frame Access Technologies Op
Slide 15: New Global Showcase Site
New Global Showcase Site ClearPoint Global Training & Innovation Center — Solana Beach, CA ¢ Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback * Showcase new technologies to Pharmaceutical and BCI partners * Home for Clinical Sp
Slide 16: Pillar Growth Strategy by 2025
4 Pillar Growth Strategy by 2025 Target Indications of > 1,000,000 Patients Diagnosed Each Year Potential Total Addressable Market for CLPT of $12B+ 2022 es CLEARPOINT ACHIEVE GLOBAL SCALE Expand Global Footprint to 100 Centers Open WW Training / Remote Support Facility Launch Robotic Platform into
Slide 17: CLPT Capabilities Executive Summary
CLPT Capabilities Executive Summary = Unique platform technology Fad enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Pipeline of new revenue streams ae from product improvements, biologic and drug delivery partnerships and services, stan
Slide 18: Nasdaq
2 ie Nasdaq Composite Nasdaq100 so at 99 + 0.18% COMP 40.20% 40.29% DJI v0. ae 0.18% +19.21 9,731.18 +2788 9,623.58 c °. amazon” prt ol Bee 0.74% wa ee00 aS Rid COMCAST pepsico matchaioup ER guesa *0,04% Pep *0.36% rcH *1,72% SBUX 10.72% AMZN a © 2022 CLEARPOINT NEURO -\ A Sk =
Slide 19: ClearPoint Neuro
CLEARPOINT NEURO S A, Wy emit = AZ CL pS \\ ZX" Si] NSE RA